Precision BioSciences, Inc. announced on September 8, 2025, that it will be issued U.S. Patent No. 12,410,418 by the U.S. Patent and Trademark Office on September 9, 2025. The patent, titled 'Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B Virus genome,' covers the PBGENE-HBV ARCUS nuclease.
This patent significantly reinforces the company's intellectual property portfolio for its lead in vivo gene editing program, PBGENE-HBV, providing U.S. patent protection into March 2042. Similar composition of matter claims were granted in Europe and Hong Kong earlier in the year.
The company also provided an update on the Phase 1 ELIMINATE-B trial, confirming that dosing of Cohort 3 was initiated in the third quarter of 2025, while repeat doses in Cohort 2 continued. This progress supports the therapeutic strategy of optimizing dose and schedule to achieve complete cures for chronic Hepatitis B patients, with further data updates expected in 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.